27828791|t|Efficacy and Safety of Vernakalant for Cardioversion of Recent-onset Atrial Fibrillation in the Asia - Pacific Region: A Phase 3 Randomized Controlled Trial
27828791|a|Atrial fibrillation (AF) is a common clinically significant cardiac arrhythmia. This phase 3 randomized, double-blind, placebo-controlled trial assessed the efficacy and safety of vernakalant hydrochloride for the pharmacological conversion of AF to sinus rhythm in patients with recent-onset (>3 hours to â‰¤7 days) symptomatic AF from the Asia - Pacific region. Patients received an infusion of vernakalant (3 mg/kg) or placebo for 10 minutes. If AF had not been terminated 15 minutes later, a second infusion of vernakalant (2 mg/kg) or placebo for 15 minutes was administered. The primary efficacy end point was conversion of AF to sinus rhythm for >1 minute within 90 minutes. The study was terminated early for administrative reasons; 123 patients from Korea, Taiwan, and India were randomized to receive vernakalant (n = 55) or placebo (n = 56). A greater proportion of patients who received vernakalant (52.7%) than placebo (12.5%) met the primary end point (P < 0.001), and cardioversion was faster in the vernakalant group than in the placebo group (P < 0.001). Vernakalant was generally well tolerated; the incidence of treatment-emergent adverse events was similar between the groups. We conclude that vernakalant is efficacious in the rapid cardioversion of recent-onset AF in patients from the Asia - Pacific region.
27828791	0	8	Efficacy	T080	C1280519
27828791	13	19	Safety	T068	C0036043
27828791	23	34	Vernakalant	T109,T121	C2001572
27828791	39	52	Cardioversion	T061	C0199550
27828791	56	88	Recent-onset Atrial Fibrillation	T047	C0741281
27828791	96	100	Asia	T083	C0003980
27828791	103	117	Pacific Region	UnknownType	C0681784
27828791	121	128	Phase 3	T079	C0439561
27828791	129	156	Randomized Controlled Trial	T062	C0206035
27828791	157	176	Atrial fibrillation	T047	C0004238
27828791	178	180	AF	T047	C0004238
27828791	217	235	cardiac arrhythmia	T033	C0003811
27828791	242	249	phase 3	T079	C0439561
27828791	250	300	randomized, double-blind, placebo-controlled trial	T062	C0206035
27828791	301	309	assessed	T052	C1516048
27828791	314	322	efficacy	T080	C1280519
27828791	327	333	safety	T068	C0036043
27828791	337	362	vernakalant hydrochloride	T109,T121	C3528638
27828791	371	386	pharmacological	T169	C0205464
27828791	387	397	conversion	T169	C0439836
27828791	401	403	AF	T047	C0004238
27828791	407	419	sinus rhythm	T033	C0232201
27828791	423	431	patients	T101	C0030705
27828791	472	486	symptomatic AF	UnknownType	C0741283
27828791	496	500	Asia	T083	C0003980
27828791	503	517	Pacific region	UnknownType	C0681784
27828791	519	527	Patients	T101	C0030705
27828791	528	536	received	T080	C1514756
27828791	540	548	infusion	T169	C1827465
27828791	552	563	vernakalant	T109,T121	C2001572
27828791	577	584	placebo	T122	C1696465
27828791	604	606	AF	T047	C0004238
27828791	658	666	infusion	T169	C1827465
27828791	670	681	vernakalant	T109,T121	C2001572
27828791	695	702	placebo	T122	C1696465
27828791	722	734	administered	T169	C1521801
27828791	740	747	primary	T080	C0205225
27828791	748	756	efficacy	T080	C1280519
27828791	757	766	end point	T080	C2349179
27828791	771	781	conversion	T169	C0439836
27828791	785	787	AF	T047	C0004238
27828791	791	803	sinus rhythm	T033	C0232201
27828791	841	846	study	T062	C2603343
27828791	851	861	terminated	T169	C2348570
27828791	872	886	administrative	T033	C3845829
27828791	887	894	reasons	T033	C3841427
27828791	900	908	patients	T101	C0030705
27828791	914	919	Korea	T083	C0022771
27828791	921	927	Taiwan	T083	C0039260
27828791	933	938	India	T083	C0021201
27828791	944	954	randomized	T062	C0034656
27828791	958	965	receive	T080	C1514756
27828791	966	977	vernakalant	T109,T121	C2001572
27828791	990	997	placebo	T122	C1696465
27828791	1032	1040	patients	T101	C0030705
27828791	1045	1053	received	T080	C1514756
27828791	1054	1065	vernakalant	T109,T121	C2001572
27828791	1079	1086	placebo	T122	C1696465
27828791	1103	1110	primary	T080	C0205225
27828791	1111	1120	end point	T080	C2349179
27828791	1138	1151	cardioversion	T061	C0199550
27828791	1170	1181	vernakalant	T109,T121	C2001572
27828791	1182	1187	group	T078	C0441833
27828791	1200	1207	placebo	T122	C1696465
27828791	1208	1213	group	T078	C0441833
27828791	1227	1238	Vernakalant	T109,T121	C2001572
27828791	1273	1282	incidence	T081	C0021149
27828791	1286	1319	treatment-emergent adverse events	T046	C0877248
27828791	1344	1350	groups	T078	C0441833
27828791	1369	1380	vernakalant	T109,T121	C2001572
27828791	1409	1422	cardioversion	T061	C0199550
27828791	1426	1441	recent-onset AF	T047	C0741281
27828791	1445	1453	patients	T101	C0030705
27828791	1463	1467	Asia	T083	C0003980
27828791	1470	1484	Pacific region	UnknownType	C0681784